The UPCI Chemical Biology Facility (ChBF) has emerged from an innovative UPCI-supported pilot project to become a new Shared Facility. The overall goal ofthe ChBF is to ensure that UPCI members have access to the most modern chemical biology reagents, instrumentation, and personnel, which will enable them to identify unique chemical probes and potential anticancer leads for further optimization. The ChBF will provide high quality support services to UPCI researchers for: 1) high throughput screening (HTS) and high content screening (HCS) assay design, development, validation, and implementation, 2) small molecule and siRNA library distribution, 3) lead characterization and optimization, and 4) data analysis. A component ofthe ChBF's service will include supplying high quality, professional access to multiple automated liquid handlers for use in 96- and 384-well plate formats, detectors, large chemical libraries, siRNA libraries, chemical informatics, chemical analysis, analog acquisition, and sophisticated data analysis software. The ChBF will collaborate with UPCI faculty, staff, and trainees in developing and conducting cancer-relevant, cell-free and cell-based HTS and HCS assays. Training will be offered either on an individual or group basis depending on the perceived need or formal requests for training. Availability of ChBF resources will be disseminated through posts on the UPCI website, emails to UPCI members, and annual workshops, seminars, and poster presentations at the UPCI retreat. The ChBF is especially interested in promoting innovative assays at UPCI. Therefore, it will encourage the development and implementation of challenging cancer-related assays. In particular, the ChBF will promote novel HCS assays focused on targets that have traditionally been considered """"""""undruggable"""""""" as an innovative component of its activity within UPCI. The ChBF creates a starting point for the identification of unique chemical probes and lead structures for potential new therapies for all of UPCI's Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-25
Application #
8519334
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
25
Fiscal Year
2013
Total Cost
$148,023
Indirect Cost
$69,738
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Li, Xiang; George, Subin M; Vernetti, Lawrence et al. (2018) A glass-based, continuously zonated and vascularized human liver acinus microphysiological system (vLAMPS) designed for experimental modeling of diseases and ADME/TOX. Lab Chip 18:2614-2631
Singh, Renu; Mehrotra, Shailly; Gopalakrishnan, Mathangi et al. (2018) Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemother Pharmacol :
Li, Changfeng; Zhang, Ying; Cheng, Xing et al. (2018) PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. Dev Cell 46:441-455.e8
Welty, Starr; Teng, Yaqun; Liang, Zhuobin et al. (2018) RAD52 is required for RNA-templated recombination repair in post-mitotic neurons. J Biol Chem 293:1353-1362
Posluszny, Donna M; Bovbjerg, Dana H; Syrjala, Karen L et al. (2018) Correlates of anxiety and depression symptoms among patients and their family caregivers prior to allogeneic hematopoietic cell transplant for hematological malignancies. Support Care Cancer :
Pulopulos, Matias M; Kozusznik, Malgorzata W (2018) The moderating role of meaning in life in the relationship between perceived stress and diurnal cortisol. Stress 21:203-210
Nehmeh, Sadek A; Schwartz, Jazmin; Grkovski, Milan et al. (2018) Inter-operator variability in compartmental kinetic analysis of 18F-fluoromisonidazole dynamic PET. Clin Imaging 49:121-127
Woodcock, Chen-Shan Chen; Huang, Yi; Woodcock, Steven R et al. (2018) Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth. J Biol Chem 293:1120-1137
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Du, Tian; Sikora, Matthew J; Levine, Kevin M et al. (2018) Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res 20:106

Showing the most recent 10 out of 1187 publications